- Affimed N.V. (AFMD, Financial) announces acceptance of three abstracts for presentation at the 2025 ASCO Annual Meeting.
- Presentations include phase 2 LuminICE-203 study results and AFM24 combination studies in NSCLC.
- The full abstracts will be published online on May 22, 2025.
Affimed N.V. (AFMD), a clinical-stage immuno-oncology company, has announced that three of its abstracts have been accepted for presentation at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3, 2025. The abstracts highlight significant progress in their clinical development programs.
The first abstract, which has been accepted for an oral presentation on May 30, covers results from the completed dose-finding part of the phase 2 LuminICE-203 study. This study investigates the efficacy of Affimed's innate cell engager acimtamig in combination with AlloNK® (AB-101) for treating relapsed or refractory classical Hodgkin lymphoma (abstract number 7008).
Additionally, two poster presentations focusing on the combination therapy of AFM24 with atezolizumab in non-small cell lung cancer (NSCLC) will take place on June 2. One poster targets EGFR-expressing NSCLC without driver mutations (abstract number 2609), while the other addresses NSCLC with EGFR kinase domain mutations (abstract number 2610). Both sessions will be part of the Developmental Therapeutics—Immunotherapy track.
Affimed continues to advance its clinical pipeline, demonstrating a robust approach to leveraging the innate immune system to target and destroy cancer cells. More comprehensive details about these studies will be available when the full abstracts are published online on May 22, 2025. Interested parties can find more information about the ASCO Annual Meeting on the official ASCO website.
